{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T16:35:03Z","timestamp":1792859703579,"version":"4.5.0"},"reference-count":220,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004252","name":"Qatar University","doi-asserted-by":"publisher","award":["IRCC-738"],"award-info":[{"award-number":["IRCC-738"]}],"id":[{"id":"10.13039\/501100004252","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discover Nano"],"DOI":"10.1186\/s11671-026-04450-8","type":"journal-article","created":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T06:23:36Z","timestamp":1770359016000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Nanoparticle approaches for hepatitis therapy and clinical translation"],"prefix":"10.1186","volume":"21","author":[{"given":"Nura Adam","family":"Mohamed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farah","family":"Atifi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zineb","family":"Ourradi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Crovella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moutaz","family":"Derbala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadi M.","family":"Yassine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ejaife O.","family":"Agbani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yahye","family":"Merhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Younes","family":"Zaid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haissam","family":"Abou-Saleh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,6]]},"reference":[{"issue":"7","key":"4450_CR1","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1073\/pnas.91.7.2401","volume":"91","author":"RH Purcell","year":"1994","unstructured":"Purcell RH. Hepatitis viruses: changing patterns of human disease. Proc Natl Acad Sci USA. 1994;91(7):2401\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"4450_CR2","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jhep.2018.09.014","volume":"70","author":"SK Asrani","year":"2019","unstructured":"Asrani SK, et al. Burden of liver diseases in the world. J Hepatol. 2019;70(1):151\u201371.","journal-title":"J Hepatol"},{"key":"4450_CR3","doi-asserted-by":"publisher","first-page":"S331","DOI":"10.1016\/S1590-8658(11)60589-6","volume":"43","author":"M Guido","year":"2011","unstructured":"Guido M, Mangia A, Faa G. Chronic viral hepatitis: the histology report. Dig Liver Dis. 2011;43:S331\u201343.","journal-title":"Dig Liver Dis"},{"key":"4450_CR4","unstructured":"WHO. Global hepatitis report 2024: action for access in low-and middle-income countries. 2024 [cited 2025 31 May 2025]."},{"key":"4450_CR5","unstructured":"Organization, W.H. Hepatitis A. 2025. 2025 [cited 2025 31 May 2025]."},{"key":"4450_CR6","unstructured":"Organization, W.H. Global hepatitis report 2024: action for access in low-and middle-income countries. 2024 [cited 2025 31 May 2025]."},{"issue":"7","key":"4450_CR7","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1007\/s11095-010-0112-z","volume":"27","author":"ML Cuestas","year":"2010","unstructured":"Cuestas ML, et al. Drug delivery systems and liver targeting for the improved pharmacotherapy of the hepatitis B virus (HBV) infection. Pharm Res. 2010;27(7):1184\u2013202.","journal-title":"Pharm Res"},{"issue":"10","key":"4450_CR8","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1007\/s40262-019-00774-0","volume":"58","author":"EJ Smolders","year":"2019","unstructured":"Smolders EJ, et al. Viral hepatitis C therapy: pharmacokinetic and pharmacodynamic considerations: a 2019 update. Clin Pharmacokinet. 2019;58(10):1237\u201363.","journal-title":"Clin Pharmacokinet"},{"issue":"Suppl 1","key":"4450_CR9","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1055\/s-2004-828675","volume":"24","author":"RP Perrillo","year":"2004","unstructured":"Perrillo RP. Overview of treatment of hepatitis B: key approaches and clinical challenges. Semin Liver Dis. 2004;24(Suppl 1):23\u20139.","journal-title":"Semin Liver Dis"},{"issue":"2","key":"4450_CR10","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1080\/1040841X.2017.1329277","volume":"44","author":"I Shahid","year":"2018","unstructured":"Shahid I, et al. Real-world challenges for hepatitis C virus medications: a critical overview. Crit Rev Microbiol. 2018;44(2):143\u201360.","journal-title":"Crit Rev Microbiol"},{"issue":"8","key":"4450_CR11","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/nri.2016.69","volume":"16","author":"EC Shin","year":"2016","unstructured":"Shin EC, Sung PS, Park SH. Immune responses and immunopathology in acute and chronic viral hepatitis. Nat Rev Immunol. 2016;16(8):509\u201323.","journal-title":"Nat Rev Immunol"},{"issue":"26","key":"4450_CR12","doi-asserted-by":"publisher","first-page":"4018","DOI":"10.3748\/wjg.v27.i26.4018","volume":"27","author":"MB Pisano","year":"2021","unstructured":"Pisano MB, et al. Viral hepatitis update: progress and perspectives. World J Gastroenterol. 2021;27(26):4018\u201344.","journal-title":"World J Gastroenterol"},{"issue":"2","key":"4450_CR13","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1002\/j.2040-4603.2013.tb00503.x","volume":"3","author":"DP Bogdanos","year":"2013","unstructured":"Bogdanos DP, Gao B, Gershwin ME. Liver immunology. Compr Physiol. 2013;3(2):567.","journal-title":"Compr Physiol"},{"key":"4450_CR14","first-page":"31","volume":"2","author":"A Maus","year":"2021","unstructured":"Maus A, Strait L, Zhu D. Nanoparticles as delivery vehicles for antiviral therapeutic drugs. Eng Regen. 2021;2:31\u201346.","journal-title":"Eng Regen"},{"key":"4450_CR15","unstructured":"(WHO), W.H.O., Hepatitis A, B, C, D, and E \u2013 Fact Sheets. 2023\u20132024. [cited 2025 24\/06\/2025]; Available from: https:\/\/www.who.int\/news-room\/fact-sheets."},{"key":"4450_CR16","unstructured":"Collaborators and G.B.o.D.G, Global, regional, and national burden of viral hepatitis, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Gastroenterol Hepatol, 2020. 5(10): p. 917\u201347."},{"key":"4450_CR17","unstructured":"(WHO), W.H.O., Hepatitis D Fact Sheet. 2023. [cited 2025 24\/06\/2025]; Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-d."},{"issue":"3","key":"4450_CR18","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.jhep.2018.11.010","volume":"70","author":"A Rasche","year":"2019","unstructured":"Rasche A, et al. Evolutionary biology of human hepatitis viruses. J Hepatol. 2019;70(3):501\u201320.","journal-title":"J Hepatol"},{"issue":"10","key":"4450_CR19","doi-asserted-by":"publisher","first-page":"707","DOI":"10.2217\/fvl-2020-0158","volume":"15","author":"A Tallan","year":"2020","unstructured":"Tallan A, Feng Z. Virus spread in the liver: mechanisms, commonalities, and unanswered questions. Future Virol. 2020;15(10):707\u201315.","journal-title":"Future Virol"},{"issue":"6","key":"4450_CR20","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.3390\/cells9061486","volume":"9","author":"C Herrscher","year":"2020","unstructured":"Herrscher C, Roingeard P, Blanchard E. Hepatitis B virus entry into cells. Cells. 2020;9(6):1486.","journal-title":"Cells"},{"issue":"1","key":"4450_CR21","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1056\/NEJMra2212151","volume":"389","author":"T Asselah","year":"2023","unstructured":"Asselah T, Rizzetto M. Hepatitis D virus infection. N Engl J Med. 2023;389(1):58\u201370.","journal-title":"N Engl J Med"},{"issue":"16","key":"4450_CR22","doi-asserted-by":"publisher","first-page":"6030","DOI":"10.1128\/MCB.20.16.6030-6039.2000","volume":"20","author":"LE Modahl","year":"2000","unstructured":"Modahl LE, et al. RNA-dependent replication and transcription of hepatitis delta virus RNA involve distinct cellular RNA polymerases. Mol Cell Biol. 2000;20(16):6030\u20139.","journal-title":"Mol Cell Biol"},{"issue":"1","key":"4450_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/nrdp.2017.6","volume":"3","author":"MP Manns","year":"2017","unstructured":"Manns MP, et al. Hepatitis C virus infection. Nat Rev Dis Primers. 2017;3(1):1\u201319.","journal-title":"Nat Rev Dis Primers"},{"issue":"3","key":"4450_CR24","doi-asserted-by":"publisher","first-page":"a033464","DOI":"10.1101\/cshperspect.a033464","volume":"9","author":"Z Feng","year":"2019","unstructured":"Feng Z, Lemon SM. Innate immunity to enteric hepatitis viruses. Cold Spring Harb Perspect Med. 2019;9(3):a033464.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"4450_CR25","doi-asserted-by":"crossref","unstructured":"Thomas, E. and T.F. Baumert. Hepatitis B virus\u2013hepatocyte interactions and innate immune responses: experimental models and molecular mechanisms. in Seminars in liver disease. 2019. Thieme Medical Publishers.","DOI":"10.1055\/s-0039-1685518"},{"issue":"7","key":"4450_CR26","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1038\/nm.3251","volume":"19","author":"B Rehermann","year":"2013","unstructured":"Rehermann B. Pathogenesis of chronic viral hepatitis: differential roles of T cells and NK cells. Nat Med. 2013;19(7):859\u201368.","journal-title":"Nat Med"},{"issue":"6","key":"4450_CR27","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1016\/j.jhep.2015.07.014","volume":"63","author":"S Luangsay","year":"2015","unstructured":"Luangsay S, et al. Early inhibition of hepatocyte innate responses by hepatitis B virus. J Hepatol. 2015;63(6):1314\u201322.","journal-title":"J Hepatol"},{"issue":"1","key":"4450_CR28","doi-asserted-by":"publisher","first-page":"44544","DOI":"10.1038\/srep44544","volume":"7","author":"J Shi","year":"2017","unstructured":"Shi J, et al. Activated hepatic stellate cells impair NK cell anti-fibrosis capacity through a TGF-\u03b2-dependent emperipolesis in HBV cirrhotic patients. Sci Rep. 2017;7(1):44544.","journal-title":"Sci Rep"},{"issue":"4","key":"4450_CR29","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1002\/j.2040-4603.2015.tb00660.x","volume":"5","author":"KK S\u00f8rensen","year":"2015","unstructured":"S\u00f8rensen KK, et al. Liver sinusoidal endothelial cells. Compr Physiol. 2015;5(4):1751\u201374.","journal-title":"Compr Physiol"},{"key":"4450_CR30","doi-asserted-by":"publisher","first-page":"735573","DOI":"10.3389\/fphys.2021.735573","volume":"12","author":"K Szafranska","year":"2021","unstructured":"Szafranska K, et al. The wHole story about fenestrations in LSEC. Front Physiol. 2021;12:735573.","journal-title":"Front Physiol"},{"issue":"6","key":"4450_CR31","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1002\/hep.27254","volume":"60","author":"IN Crispe","year":"2014","unstructured":"Crispe IN. Immune tolerance in liver disease. Hepatology. 2014;60(6):2109\u201317.","journal-title":"Hepatology"},{"issue":"23","key":"4450_CR32","doi-asserted-by":"publisher","first-page":"3249","DOI":"10.3748\/wjg.v27.i23.3249","volume":"27","author":"PH Almeida","year":"2021","unstructured":"Almeida PH, et al. Update on the management and treatment of viral hepatitis. World J Gastroenterol. 2021;27(23):3249.","journal-title":"World J Gastroenterol"},{"key":"4450_CR33","first-page":"111748","volume":"142","author":"L Bana","year":"2021","unstructured":"Bana L, Minnelli C, Pazzi D, Gugliotta A, Bragazzi NL, Armeni T. Hepatitis C virus infection and nanoparticles: a promising therapeutic approach. Biomed Pharmacother. 2021;142:111748.","journal-title":"Biomed Pharmacother"},{"issue":"9","key":"4450_CR34","doi-asserted-by":"publisher","first-page":"103052","DOI":"10.1016\/j.isci.2021.103052","volume":"24","author":"J Mao","year":"2021","unstructured":"Mao J, et al. Comprehensive strategies of machine-learning-based quantitative structure-activity relationship models. iScience. 2021;24(9):103052.","journal-title":"iScience"},{"key":"4450_CR35","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222011227","author":"J Miao","year":"2021","unstructured":"Miao J, et al. Advances in nanoparticle drug delivery systems for anti-hepatitis B virus therapy: a narrative review. Int J Mol Sci. 2021. https:\/\/doi.org\/10.3390\/ijms222011227.","journal-title":"Int J Mol Sci"},{"key":"4450_CR36","doi-asserted-by":"crossref","first-page":"1265446","DOI":"10.3389\/fddev.2023.1265446","volume":"3","author":"B Tang","year":"2023","unstructured":"Tang B, Wang Y, Xu Y, Zheng J, Lin J. Engineering nanoparticles for the treatment of viral hepatitis: progress and perspectives. Front Drug Deliv. 2023;3:1265446.","journal-title":"Front Drug Deliv"},{"issue":"10","key":"4450_CR37","first-page":"11227","volume":"22","author":"Y Liu","year":"2018","unstructured":"Liu Y, Jiang Y, Zhang M, Tang Z, He M, Bu Y, et al. Chitosan-based polymeric nanoparticles for improved antiviral drug delivery: a review. Int J Mol Sci. 2018;22(10):11227.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"4450_CR38","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3390\/v10050267","volume":"10","author":"S Majeed","year":"2018","unstructured":"Majeed S, Iqbal Z, Anjum F, Yousaf M, Rehman A. Hepatitis C virus and vaccine development. Viruses. 2018;10(5):267.","journal-title":"Viruses"},{"issue":"1","key":"4450_CR39","first-page":"13","volume":"4","author":"S Hekmat","year":"2017","unstructured":"Hekmat S, ShafieeArdestani M, AM, et al. Preparation and characterization of PLGA nanoparticles containing recombinant core\u2013NS3 fusion protein of hepatitis C virus as a nano-vaccine candidate. Vaccine Res. 2017;4(1):13\u20138.","journal-title":"Vaccine Res"},{"issue":"22","key":"4450_CR40","doi-asserted-by":"publisher","first-page":"2931","DOI":"10.1002\/adhm.201600416","volume":"5","author":"HJ Park","year":"2016","unstructured":"Park HJ, et al. Galactosylated lipidoid nanoparticles for delivery of small interfering RNA to inhibit hepatitis C viral replication in Vivo. Adv Healthc Mater. 2016;5(22):2931\u201341.","journal-title":"Adv Healthc Mater"},{"key":"4450_CR41","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1002\/adfm.201604139","volume":"27","author":"MS Draz","year":"2017","unstructured":"Draz MS, et al. Electrically oscillating plasmonic nanoparticles for enhanced DNA vaccination against hepatitis C virus. Adv Funct Mater. 2017;27:50.","journal-title":"Adv Funct Mater"},{"issue":"1","key":"4450_CR42","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.cimid.2010.02.003","volume":"34","author":"Y Yang","year":"2011","unstructured":"Yang Y, et al. Immunogenicity of multiple-epitope antigen gene of HCV carried by novel biodegradable polymers. Comp Immunol Microbiol Infect Dis. 2011;34(1):65\u201372.","journal-title":"Comp Immunol Microbiol Infect Dis"},{"issue":"13-14","key":"4450_CR43","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/j.clinbiochem.2010.07.001","volume":"43","author":"SM Shawky","year":"2010","unstructured":"Shawky SM, Bald D, Azzazy HM. Direct detection of unamplified hepatitis C virus RNA using unmodified gold nanoparticles. Clin Biochem. 2010;43(13\u201314):1163\u20138.","journal-title":"Clin Biochem"},{"key":"4450_CR44","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.addr.2020.06.017","volume":"154-155","author":"R B\u00f6ttger","year":"2020","unstructured":"B\u00f6ttger R, et al. Lipid-based nanoparticle technologies for liver targeting. Adv Drug Deliv Rev. 2020;154\u2013155:79\u2013101.","journal-title":"Adv Drug Deliv Rev"},{"issue":"12","key":"4450_CR45","doi-asserted-by":"publisher","first-page":"4005","DOI":"10.1002\/jps.24219","volume":"103","author":"T Ishihara","year":"2014","unstructured":"Ishihara T, Kaneko K, Mizushima T. Development of biodegradable nanoparticles for liver-specific ribavirin delivery. J Pharm Sci. 2014;103(12):4005\u201311.","journal-title":"J Pharm Sci"},{"issue":"11","key":"4450_CR46","doi-asserted-by":"publisher","first-page":"9522","DOI":"10.1021\/nn302538y","volume":"6","author":"MY Lee","year":"2012","unstructured":"Lee MY, et al. Hyaluronic acid-gold nanoparticle\/interferon \u03b1 complex for targeted treatment of hepatitis C virus infection. ACS Nano. 2012;6(11):9522\u201331.","journal-title":"ACS Nano"},{"issue":"8","key":"4450_CR47","doi-asserted-by":"publisher","first-page":"2852","DOI":"10.3109\/10717544.2015.1108375","volume":"23","author":"S Mehrlatifan","year":"2016","unstructured":"Mehrlatifan S, et al. The structural HCV genes delivered by MPG cell penetrating peptide are directed to enhance immune responses in mice model. Drug Deliv. 2016;23(8):2852\u20139.","journal-title":"Drug Deliv"},{"issue":"15","key":"4450_CR48","doi-asserted-by":"publisher","first-page":"3846","DOI":"10.1016\/j.biomaterials.2013.01.026","volume":"34","author":"J Zhang","year":"2013","unstructured":"Zhang J, et al. Antiviral peptide nanocomplexes as a potential therapeutic modality for HIV\/HCV co-infection. Biomaterials. 2013;34(15):3846\u201357.","journal-title":"Biomaterials"},{"key":"4450_CR49","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.biomaterials.2015.08.014","volume":"70","author":"J Zhang","year":"2015","unstructured":"Zhang J, et al. Liver-targeted antiviral peptide nanocomplexes as potential anti-HCV therapeutics. Biomaterials. 2015;70:37\u201347.","journal-title":"Biomaterials"},{"key":"4450_CR50","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3390\/nano14090743","volume":"14","author":"SA Solorio-Rodriguez","year":"2024","unstructured":"Solorio-Rodriguez SA, et al. A systematic genotoxicity assessment of a suite of metal oxide nanoparticles reveals their DNA damaging and clastogenic potential. Nanomaterials (Basel). 2024;14:9.","journal-title":"Nanomaterials (Basel)"},{"key":"4450_CR51","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1590\/1678-457X.6515","volume":"35","author":"DDM Carvalho","year":"2015","unstructured":"Carvalho DDM, GeraldineMouraTorres TRMCJDMCL. Production, solubility and antioxidant activity of curcumin nanosuspension. Food Sci Technol. 2015;35:115\u20139.","journal-title":"Food Sci Technol"},{"issue":"7","key":"4450_CR52","doi-asserted-by":"publisher","first-page":"e0200218","DOI":"10.1371\/journal.pone.0200218","volume":"13","author":"DH Alshora","year":"2018","unstructured":"Alshora DH, et al. Rosuvastatin calcium nanoparticles: improving bioavailability by formulation and stabilization codesign. PLoS One. 2018;13(7):e0200218.","journal-title":"PLoS One"},{"issue":"10","key":"4450_CR53","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1136\/gutjnl-2016-312019","volume":"66","author":"CH Liu","year":"2017","unstructured":"Liu CH, et al. Highly bioavailable silibinin nanoparticles inhibit HCV infection. Gut. 2017;66(10):1853\u201361.","journal-title":"Gut"},{"issue":"6","key":"4450_CR54","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1016\/j.nano.2016.02.015","volume":"12","author":"JS Moon","year":"2016","unstructured":"Moon JS, et al. Inhibition of hepatitis C virus in mouse models by lipidoid nanoparticle-mediated systemic delivery of siRNA against PRK2. Nanomedicine. 2016;12(6):1489\u201398.","journal-title":"Nanomedicine"},{"issue":"1","key":"4450_CR55","doi-asserted-by":"publisher","first-page":"1418133","DOI":"10.1080\/2331205X.2017.1418133","volume":"4","author":"KL Kaneko","year":"2017","unstructured":"Kaneko KL. Development of liver-specific ribavirin-loaded nanoparticles with reduced cytotoxicity. Cogent Med. 2017;4(1):1418133.","journal-title":"Cogent Med"},{"issue":"11","key":"4450_CR56","doi-asserted-by":"publisher","first-page":"2931","DOI":"10.1007\/s11095-011-0561-z","volume":"28","author":"HI Labouta","year":"2011","unstructured":"Labouta HI, et al. Gold nanoparticle penetration and reduced metabolism in human skin by toluene. Pharm Res. 2011;28(11):2931\u201344.","journal-title":"Pharm Res"},{"issue":"15","key":"4450_CR57","doi-asserted-by":"publisher","first-page":"4164","DOI":"10.1073\/pnas.1522080113","volume":"113","author":"HJ Li","year":"2016","unstructured":"Li HJ, et al. Stimuli-responsive clustered nanoparticles for improved tumor penetration and therapeutic efficacy. Proc Natl Acad Sci USA. 2016;113(15):4164\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"48","key":"4450_CR58","doi-asserted-by":"publisher","first-page":"20709","DOI":"10.1073\/pnas.1005211107","volume":"107","author":"W Lee","year":"2010","unstructured":"Lee W, et al. Hydrophobic nanoparticles improve permeability of cell-encapsulating poly(ethylene glycol) hydrogels while maintaining patternability. Proc Natl Acad Sci USA. 2010;107(48):20709\u201314.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"4450_CR59","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.nano.2008.07.007","volume":"5","author":"PP Karmali","year":"2009","unstructured":"Karmali PP, et al. Targeting of albumin-embedded paclitaxel nanoparticles to tumors. Nanomedicine. 2009;5(1):73\u201382.","journal-title":"Nanomedicine"},{"key":"4450_CR60","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.carbpol.2018.04.052","volume":"195","author":"X Wang","year":"2018","unstructured":"Wang X, et al. Enhanced delivery of doxorubicin to the liver through self-assembled nanoparticles formed via conjugation of glycyrrhetinic acid to the hydroxyl group of hyaluronic acid. Carbohydr Polym. 2018;195:170\u20139.","journal-title":"Carbohydr Polym"},{"issue":"1","key":"4450_CR61","doi-asserted-by":"publisher","first-page":"19","DOI":"10.2147\/nano.2007.2.1.19","volume":"2","author":"T Thomas","year":"2007","unstructured":"Thomas T, Foster G. Nanomedicines in the treatment of chronic hepatitis C\u2013focus on pegylated interferon alpha-2a. Int J Nanomedicine. 2007;2(1):19\u201324.","journal-title":"Int J Nanomedicine"},{"issue":"31","key":"4450_CR62","doi-asserted-by":"publisher","first-page":"12387","DOI":"10.1073\/pnas.1207766109","volume":"109","author":"Z Wang","year":"2012","unstructured":"Wang Z, et al. Nanoparticle-based artificial RNA silencing machinery for antiviral therapy. Proc Natl Acad Sci USA. 2012;109(31):12387\u201392.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"9","key":"4450_CR63","doi-asserted-by":"publisher","first-page":"2754","DOI":"10.1016\/j.biomaterials.2011.12.015","volume":"33","author":"SR Ryoo","year":"2012","unstructured":"Ryoo SR, et al. Functional delivery of DNAzyme with iron oxide nanoparticles for hepatitis C virus gene knockdown. Biomaterials. 2012;33(9):2754\u201361.","journal-title":"Biomaterials"},{"issue":"2","key":"4450_CR64","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1111\/apt.15575","volume":"51","author":"CC Wang","year":"2020","unstructured":"Wang CC, Cheng PN, Kao JH. Systematic review: chronic viral hepatitis and metabolic derangement. Aliment Pharmacol Ther. 2020;51(2):216\u201330.","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"4450_CR65","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/s41541-023-00635-9","volume":"8","author":"T Patra","year":"2023","unstructured":"Patra T, et al. Hepatitis C virus E1 and modified E2 delivered from an mRNA vaccine induces protective immunity. NPJ Vaccines. 2023;8(1):42.","journal-title":"NPJ Vaccines"},{"issue":"4","key":"4450_CR66","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1002\/hep.32181","volume":"75","author":"EJ Lawitz","year":"2022","unstructured":"Lawitz EJ, et al. BMS-986263 in patients with advanced hepatic fibrosis: 36-week results from a randomized, placebo-controlled phase 2 trial. Hepatology. 2022;75(4):912\u201323.","journal-title":"Hepatology"},{"key":"4450_CR67","doi-asserted-by":"crossref","unstructured":"Thi TTH, S.E., Lee JS, Nguyen DH, Park KD, Truong NP., Lipid-Based Nanoparticles in the Clinic and Clinical Trials: From Cancer Nanomedicine to COVID-19 Vaccines. Vaccines (Basel), 2021. 9(4): p. 359.","DOI":"10.3390\/vaccines9040359"},{"issue":"3","key":"4450_CR68","doi-asserted-by":"publisher","first-page":"101289","DOI":"10.1016\/j.omtm.2024.101289","volume":"32","author":"H Okada","year":"2024","unstructured":"Okada H, et al. Lipid nanoparticle-encapsulated DOCK11-siRNA efficiently reduces hepatitis B virus cccDNA level in infected mice. Mol Ther Methods Clin Dev. 2024;32(3):101289.","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"2","key":"4450_CR69","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s40199-020-00355-8","volume":"28","author":"SM Abd El-Halim","year":"2020","unstructured":"Abd El-Halim SM, et al. Stabilized oral nanostructured lipid carriers of Adefovir Dipivoxil as a potential liver targeting: estimation of liver function panel and uptake following intravenous injection of radioiodinated indicator. DARU J Pharm Sci. 2020;28(2):517\u201332.","journal-title":"DARU J Pharm Sci"},{"issue":"2","key":"4450_CR70","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1208\/s12249-010-9414-z","volume":"11","author":"M Shah","year":"2010","unstructured":"Shah M, Pathak K. Development and statistical optimization of solid lipid nanoparticles of simvastatin by using 2(3) full-factorial design. AAPS PharmSciTech. 2010;11(2):489\u201396.","journal-title":"AAPS PharmSciTech"},{"key":"4450_CR71","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.nantod.2017.06.008","volume":"15","author":"S Hassan","year":"2017","unstructured":"Hassan S, et al. Evolution and clinical translation of drug delivery nanomaterials. Nano Today. 2017;15:91\u2013106.","journal-title":"Nano Today"},{"key":"4450_CR72","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.ejpb.2017.12.003","volume":"124","author":"H Wang","year":"2018","unstructured":"Wang H, et al. Single dose HBsAg CS-\u03b3-PGA nanogels induce potent protective immune responses against HBV infection. Eur J Pharm Biopharm. 2018;124:82\u20138.","journal-title":"Eur J Pharm Biopharm"},{"key":"4450_CR73","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.ejps.2018.03.016","volume":"118","author":"MM Ayoub","year":"2018","unstructured":"Ayoub MM, et al. Injectable PLGA Adefovir microspheres; the way for long term therapy of chronic hepatitis-B. Eur J Pharm Sci. 2018;118:24\u201331.","journal-title":"Eur J Pharm Sci"},{"issue":"4","key":"4450_CR74","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1016\/j.carbpol.2012.04.056","volume":"89","author":"R Subbiah","year":"2012","unstructured":"Subbiah R, et al. N,N,N-trimethyl chitosan nanoparticles for controlled intranasal delivery of HBV surface antigen. Carbohydr Polym. 2012;89(4):1289\u201397.","journal-title":"Carbohydr Polym"},{"issue":"1","key":"4450_CR75","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1208\/s12249-019-1526-5","volume":"21","author":"J Zhu","year":"2019","unstructured":"Zhu J, et al. Mannose-modified PLGA nanoparticles for sustained and targeted delivery in hepatitis B virus immunoprophylaxis. AAPS PharmSciTech. 2019;21(1):13.","journal-title":"AAPS PharmSciTech"},{"issue":"2","key":"4450_CR76","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/j.ijpharm.2015.08.056","volume":"495","author":"M Xue","year":"2015","unstructured":"Xue M, et al. Development of chitosan nanoparticles as drug delivery system for a prototype capsid inhibitor. Int J Pharm. 2015;495(2):771\u201382.","journal-title":"Int J Pharm"},{"issue":"1","key":"4450_CR77","doi-asserted-by":"publisher","first-page":"e0227231","DOI":"10.1371\/journal.pone.0227231","volume":"15","author":"M Hamdi","year":"2020","unstructured":"Hamdi M, et al. An integrated vitamin E-coated polymer hybrid nanoplatform: a lucrative option for an enhanced in vitro macrophage retention for an anti-hepatitis B therapeutic prospect. PLoS One. 2020;15(1):e0227231.","journal-title":"PLoS One"},{"issue":"3","key":"4450_CR78","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s12291-013-0355-7","volume":"29","author":"J Shahabi","year":"2014","unstructured":"Shahabi J, et al. Effect of gold nanoparticles on properties of nanoliposomal hydroxyurea: an in vitro study. Indian J Clin Biochem. 2014;29(3):315\u201320.","journal-title":"Indian J Clin Biochem"},{"issue":"33","key":"4450_CR79","doi-asserted-by":"publisher","first-page":"9477","DOI":"10.1039\/c1cc13340c","volume":"47","author":"D Tang","year":"2011","unstructured":"Tang D, et al. Electrochemical detection of hepatitis C virus with signal amplification using BamHI endonuclease and horseradish peroxidase-encapsulated nanogold hollow spheres. Chem Commun (Camb). 2011;47(33):9477\u20139.","journal-title":"Chem Commun (Camb)"},{"key":"4450_CR80","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.bios.2015.10.028","volume":"77","author":"CC Chen","year":"2016","unstructured":"Chen CC, et al. Polymerase chain reaction-free detection of hepatitis B virus DNA using a nanostructured impedance biosensor. Biosens Bioelectron. 2016;77:603\u20138.","journal-title":"Biosens Bioelectron"},{"issue":"6","key":"4450_CR81","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1039\/c0ay00774a","volume":"3","author":"R Liang","year":"2011","unstructured":"Liang R, Chen Y, Qiu J. A sensitive amperometric immunosensor for hepatitis B surface antigen based on biocompatible redoxactive chitosan\u2013toluidine blue\/gold nanoparticles composite film. Anal Methods. 2011;3(6):1338\u201343.","journal-title":"Anal Methods"},{"issue":"14","key":"4450_CR82","doi-asserted-by":"publisher","first-page":"5059","DOI":"10.1039\/C4AY00461B","volume":"6","author":"S Sabouri","year":"2014","unstructured":"Sabouri S, et al. A gold nanoparticle-based immunosensor for the chemiluminescence detection of the hepatitis B surface antigen. Anal Methods. 2014;6(14):5059\u201366.","journal-title":"Anal Methods"},{"issue":"3\u20134","key":"4450_CR83","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s00604-012-0842-1","volume":"178","author":"C Ma","year":"2012","unstructured":"Ma C, et al. Labelfree sandwich type of immunosensor for hepatitis C virus core antigen based on the use of gold nanoparticles on a nanostructured metal oxide surface. Mikrochim Acta. 2012;178(3\u20134):331\u201340.","journal-title":"Mikrochim. Acta"},{"issue":"63","key":"4450_CR84","doi-asserted-by":"publisher","first-page":"7877","DOI":"10.1039\/c2cc33635a","volume":"48","author":"W Li","year":"2012","unstructured":"Li W, et al. Catalytic signal amplification of gold nanoparticles combining with conformation-switched hairpin DNA probe for hepatitis C virus quantification. Chem Commun (Camb). 2012;48(63):7877\u20139.","journal-title":"Chem Commun (Camb)"},{"issue":"8","key":"4450_CR85","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1002\/elan.201500081","volume":"27","author":"I Moldoveanu","year":"2015","unstructured":"Moldoveanu I, Stefan-Van Staden RI, Frederick Van Staden J. Chitosan based diamond paste stochastic microsensors modified with gold nanoparticles detect hepatitis C virus core antigen. Electroanalysis. 2015;27(8):1842\u20136.","journal-title":"Electroanalysis"},{"issue":"12","key":"4450_CR86","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1007\/s00339-019-3128-1","volume":"125","author":"G Biasotto","year":"2019","unstructured":"Biasotto G, et al. ZnO nanorods-gold nanoparticle-based biosensor for detecting hepatitis C. Appl Phys A. 2019;125(12):821.","journal-title":"Appl Phys A"},{"key":"4450_CR87","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.snb.2014.08.079","volume":"205","author":"ZC Liu","year":"2014","unstructured":"Liu ZC, et al. Exonuclease III-assisted recycling amplification detection of hepatitis B virus DNA by DNA-scaffolded silver nanoclusters probe. Sens Actuators B Chem. 2014;205:219\u201326.","journal-title":"Sens Actuators B Chem"},{"key":"4450_CR88","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.aca.2019.05.066","volume":"1077","author":"F Jin","year":"2019","unstructured":"Jin F, Li H, Xu D. Enzyme-free fluorescence microarray for determination of hepatitis B virus DNA based on silver nanoparticle aggregates-assisted signal amplification. Anal Chim Acta. 2019;1077:297\u2013304.","journal-title":"Anal Chim Acta"},{"key":"4450_CR89","doi-asserted-by":"crossref","unstructured":"Shady, N.H., et al., Hepatitis C Virus NS3 Protease and Helicase Inhibitors from Red Sea Sponge (Int J Nanomedicine, 2020. 15: p. 3377\u20133389.","DOI":"10.2147\/IJN.S233766"},{"issue":"Pt 2","key":"4450_CR90","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1016\/j.bios.2016.09.086","volume":"89","author":"A Valipour","year":"2017","unstructured":"Valipour A, Roushani M. Using silver nanoparticle and thiol graphene quantum dots nanocomposite as a substratum to load antibody for detection of hepatitis C virus core antigen: electrochemical oxidation of riboflavin was used as redox probe. Biosens Bioelectron. 2017;89(Pt 2):946\u201351.","journal-title":"Biosens Bioelectron"},{"issue":"11","key":"4450_CR91","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1002\/elps.201200697","volume":"34","author":"M Vaculovicova","year":"2013","unstructured":"Vaculovicova M, et al. Integrated chip electrophoresis and magnetic particle isolation used for detection of hepatitis B virus oligonucleotides. Electrophoresis. 2013;34(11):1548\u201354.","journal-title":"Electrophoresis"},{"key":"4450_CR92","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/j.msec.2015.10.082","volume":"59","author":"MH Mashhadizadeh","year":"2016","unstructured":"Mashhadizadeh MH, Talemi RP. Synergistic effect of magnetite and gold nanoparticles onto the response of a label-free impedimetric hepatitis B virus DNA biosensor. Mater Sci Eng C Mater Biol Appl. 2016;59:773\u201381.","journal-title":"Mater Sci Eng C Mater Biol Appl"},{"issue":"4","key":"4450_CR93","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1515\/cclm-2013-0521","volume":"52","author":"SM Shawky","year":"2014","unstructured":"Shawky SM, Guirgis BS, Azzazy HM. Detection of unamplified HCV RNA in serum using a novel two metallic nanoparticle platform. Clin Chem Lab Med. 2014;52(4):565\u201372.","journal-title":"Clin Chem Lab Med"},{"key":"4450_CR94","first-page":"71","volume":"11","author":"B Mehrdad Vahdati","year":"2020","unstructured":"Mehrdad Vahdati B, et al. Synthesis of carbon nanomaterials based on graphene quantum dots and improving their surface properties via chemical modification. Modares J Biotechnol. 2020;11:71\u20136.","journal-title":"Modares J Biotechnol"},{"key":"4450_CR95","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.ab.2017.07.016","volume":"534","author":"K Ghanbari","year":"2017","unstructured":"Ghanbari K, Roushani M, Azadbakht A. Ultra-sensitive aptasensor based on a GQD nanocomposite for detection of hepatitis C virus core antigen. Anal Biochem. 2017;534:64\u20139.","journal-title":"Anal Biochem"},{"key":"4450_CR96","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.aca.2018.06.019","volume":"1035","author":"Y Hu","year":"2018","unstructured":"Hu Y, et al. A photoelectrochemical immunosensor based on gold nanoparticles\/ZnAgInS quaternary quantum dots for the high-performance determination of hepatitis B virus surface antigen. Anal Chim Acta. 2018;1035:136\u201345.","journal-title":"Anal Chim Acta"},{"key":"4450_CR97","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.bioelechem.2018.04.004","volume":"122","author":"MF Abd Muain","year":"2018","unstructured":"Abd Muain MF, et al. Gold nanoparticle-decorated reduced-graphene oxide targeting anti hepatitis B virus core antigen. Bioelectrochemistry. 2018;122:199\u2013205.","journal-title":"Bioelectrochemistry"},{"issue":"4","key":"4450_CR98","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1039\/C7RA11945C","volume":"8","author":"Q Xiang","year":"2018","unstructured":"Xiang Q, et al. A label-free electrochemical platform for the highly sensitive detection of hepatitis B virus DNA using graphene quantum dots. RSC Adv. 2018;8(4):1820\u20135.","journal-title":"RSC Adv"},{"issue":"74","key":"4450_CR99","doi-asserted-by":"publisher","first-page":"8241","DOI":"10.1039\/c3cc43368d","volume":"49","author":"S Kim","year":"2013","unstructured":"Kim S, et al. Deoxyribozyme-loaded nano-graphene oxide for simultaneous sensing and silencing of the hepatitis C virus gene in liver cells. Chem Commun (Camb). 2013;49(74):8241\u20133.","journal-title":"Chem Commun (Camb)"},{"key":"4450_CR100","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.bios.2013.03.058","volume":"47","author":"C Ma","year":"2013","unstructured":"Ma C, et al. MultisHRP-DNA-coated CMWNTs as signal labels for an ultrasensitive hepatitis C virus core antigen electrochemical immunosensor. Biosens Bioelectron. 2013;47:467\u201374.","journal-title":"Biosens Bioelectron"},{"issue":"1","key":"4450_CR101","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s12896-024-00935-5","volume":"25","author":"AA Ali","year":"2025","unstructured":"Ali AA, et al. Development of virus-like particles (VLPs) for hepatitis C virus genotype 4: a novel approach for vaccine development in Egypt. BMC Biotechnol. 2025;25(1):8.","journal-title":"BMC Biotechnol"},{"issue":"Pt 2","key":"4450_CR102","doi-asserted-by":"publisher","first-page":"141152","DOI":"10.1016\/j.ijbiomac.2025.141152","volume":"305","author":"K Fatema","year":"2025","unstructured":"Fatema K, et al. A VLP vaccine platform comprising the core protein of hepatitis B virus with N-terminal antigen capture. Int J Biol Macromol. 2025;305(Pt 2):141152.","journal-title":"Int J Biol Macromol"},{"issue":"1","key":"4450_CR103","doi-asserted-by":"publisher","first-page":"e5251","DOI":"10.1002\/pro.5251","volume":"34","author":"M Lehky","year":"2025","unstructured":"Lehky M, et al. A novel method for recombinant mammalian-expressed S-HBsAg virus-like particle production for assembly status analysis and improved anti-HBs serology. Protein Sci. 2025;34(1):e5251.","journal-title":"Protein Sci"},{"issue":"5","key":"4450_CR104","doi-asserted-by":"publisher","first-page":"e0167521","DOI":"10.1128\/jvi.01675-21","volume":"96","author":"J McGregor","year":"2022","unstructured":"McGregor J, et al. Virus-like particles containing the E2 core domain of hepatitis C virus generate broadly neutralizing antibodies in Guinea pigs. J Virol. 2022;96(5):e0167521.","journal-title":"J Virol"},{"issue":"12","key":"4450_CR105","doi-asserted-by":"publisher","first-page":"4132","DOI":"10.1096\/fj.201600696R","volume":"30","author":"Y Zhou","year":"2016","unstructured":"Zhou Y, et al. Toll-like receptor 3-activated macrophages confer anti-HCV activity to hepatocytes through exosomes. FASEB J. 2016;30(12):4132\u201340.","journal-title":"FASEB J"},{"issue":"10","key":"4450_CR106","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1002\/jps.2600831024","volume":"83","author":"R Mehvar","year":"1994","unstructured":"Mehvar R, Robinson MA, Reynolds JM. Molecular weight dependent tissue accumulation of dextrans: in vivo studies in rats. J Pharm Sci. 1994;83(10):1495\u20139.","journal-title":"J Pharm Sci"},{"issue":"3","key":"4450_CR107","doi-asserted-by":"publisher","first-page":"185","DOI":"10.2174\/1389200033489460","volume":"4","author":"JE van Montfoort","year":"2003","unstructured":"van Montfoort JE, et al. Drug uptake systems in liver and kidney. Curr Drug Metab. 2003;4(3):185\u2013211.","journal-title":"Curr Drug Metab"},{"issue":"6","key":"4450_CR108","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1021\/bc700193d","volume":"18","author":"KC Chimalakonda","year":"2007","unstructured":"Chimalakonda KC, et al. Synthesis, analysis, in vitro characterization, and in vivo disposition of a lamivudine-dextran conjugate for selective antiviral delivery to the liver. Bioconjug Chem. 2007;18(6):2097\u2013108.","journal-title":"Bioconjug Chem"},{"issue":"5","key":"4450_CR109","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1097\/01.tp.0000177654.48112.b6","volume":"81","author":"AP Chimalakonda","year":"2006","unstructured":"Chimalakonda AP, et al. Attenuation of acute rejection in a rat liver transplantation model by a liver-targeted dextran prodrug of methylprednisolone. Transplantation. 2006;81(5):678\u201385.","journal-title":"Transplantation"},{"issue":"7","key":"4450_CR110","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1002\/jps.21161","volume":"97","author":"S Penugonda","year":"2008","unstructured":"Penugonda S, et al. Synthesis and in vitro characterization of novel dextran-methylprednisolone conjugates with peptide linkers: effects of linker length on hydrolytic and enzymatic release of methylprednisolone and its peptidyl intermediates. J Pharm Sci. 2008;97(7):2649\u201364.","journal-title":"J Pharm Sci"},{"issue":"1","key":"4450_CR111","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cld.2016.08.001","volume":"21","author":"OA Almazroo","year":"2017","unstructured":"Almazroo OA, Miah MK, Venkataramanan R. Drug metabolism in the Liver. Clin Liver Dis. 2017;21(1):1\u201320.","journal-title":"Clin Liver Dis"},{"issue":"10","key":"4450_CR112","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1007\/s11095-007-9289-1","volume":"24","author":"WA Alrefai","year":"2007","unstructured":"Alrefai WA, Gill RK. Bile acid transporters: structure, function, regulation and pathophysiological implications. Pharm Res. 2007;24(10):1803\u201323.","journal-title":"Pharm Res"},{"issue":"Pt 10","key":"4450_CR113","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1242\/jeb.204.10.1673","volume":"204","author":"MV St-Pierre","year":"2001","unstructured":"St-Pierre MV, et al. Transport of bile acids in hepatic and non-hepatic tissues. J Exp Biol. 2001;204(Pt 10):1673\u201386.","journal-title":"J Exp Biol"},{"key":"4450_CR114","doi-asserted-by":"publisher","first-page":"108879","DOI":"10.1016\/j.steroids.2021.108879","volume":"173","author":"K Lei","year":"2021","unstructured":"Lei K, et al. Research progress in the application of bile acid-drug conjugates: a \u201ctrojan horse\u201d strategy. Steroids. 2021;173:108879.","journal-title":"Steroids"},{"issue":"8","key":"4450_CR115","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.3390\/12081859","volume":"12","author":"E Siev\u00e4nen","year":"2007","unstructured":"Siev\u00e4nen E. Exploitation of bile acid transport systems in prodrug design. Molecules. 2007;12(8):1859\u201389.","journal-title":"Molecules"},{"issue":"4","key":"4450_CR116","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.nantod.2015.06.006","volume":"10","author":"HH Gustafson","year":"2015","unstructured":"Gustafson HH, et al. Nanoparticle Uptake: the Phagocyte problem. Nano Today. 2015;10(4):487\u2013510.","journal-title":"Nano Today"},{"key":"4450_CR117","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.jconrel.2016.01.020","volume":"240","author":"YN Zhang","year":"2016","unstructured":"Zhang YN, et al. Nanoparticle-liver interactions: cellular uptake and hepatobiliary elimination. J Control Release. 2016;240:332\u201348.","journal-title":"J Control Release"},{"issue":"8","key":"4450_CR118","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/nnano.2007.223","volume":"2","author":"MA Dobrovolskaia","year":"2007","unstructured":"Dobrovolskaia MA, McNeil SE. Immunological properties of engineered nanomaterials. Nat Nanotechnol. 2007;2(8):469\u201378.","journal-title":"Nat Nanotechnol"},{"issue":"13","key":"4450_CR119","doi-asserted-by":"publisher","first-page":"3435","DOI":"10.1016\/j.biomaterials.2011.01.021","volume":"32","author":"K Xiao","year":"2011","unstructured":"Xiao K, et al. The effect of surface charge on in vivo biodistribution of PEG-oligocholic acid based micellar nanoparticles. Biomaterials. 2011;32(13):3435\u201346.","journal-title":"Biomaterials"},{"issue":"4","key":"4450_CR120","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.devcel.2004.09.009","volume":"7","author":"RG Parton","year":"2004","unstructured":"Parton RG. Caveolae meet endosomes: a stable relationship? Dev Cell. 2004;7(4):458\u201360.","journal-title":"Dev Cell"},{"issue":"6","key":"4450_CR121","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/j.cell.2004.09.003","volume":"118","author":"L Pelkmans","year":"2004","unstructured":"Pelkmans L, et al. Caveolin-stabilized membrane domains as multifunctional transport and sorting devices in endocytic membrane traffic. Cell. 2004;118(6):767\u201380.","journal-title":"Cell"},{"issue":"6","key":"4450_CR122","doi-asserted-by":"publisher","first-page":"673","DOI":"10.2217\/nnm.16.5","volume":"11","author":"N Hoshyar","year":"2016","unstructured":"Hoshyar N, Han Bao GSHG. The effect of nanoparticle size on in vivo pharmacokinetics and cellular interaction. Nanomedicine (Lond). 2016;11(6):673\u201392.","journal-title":"Nanomedicine (Lond)"},{"issue":"8","key":"4450_CR123","doi-asserted-by":"publisher","first-page":"2950","DOI":"10.1016\/j.bmc.2009.02.043","volume":"17","author":"AH Faraji","year":"2009","unstructured":"Faraji AH, Wipf P. Nanoparticles in cellular drug delivery. Bioorg Med Chem. 2009;17(8):2950\u201362.","journal-title":"Bioorg Med Chem"},{"issue":"3","key":"4450_CR124","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.ejpb.2010.11.010","volume":"77","author":"M Arnida","year":"2011","unstructured":"Arnida M, et al. Geometry and surface characteristics of gold nanoparticles influence their biodistribution and uptake by macrophages. Eur J Pharm Biopharm. 2011;77(3):417\u201323.","journal-title":"Eur J Pharm Biopharm"},{"issue":"3","key":"4450_CR125","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.jconrel.2009.10.014","volume":"141","author":"P Decuzzi","year":"2010","unstructured":"Decuzzi P, et al. Size and shape effects in the biodistribution of intravascularly injected particles. J Control Release. 2010;141(3):320\u20137.","journal-title":"J Control Release"},{"issue":"9\u201310","key":"4450_CR126","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1002\/smll.201201390","volume":"9","author":"X Duan","year":"2013","unstructured":"Duan X, Li Y. Physicochemical characteristics of nanoparticles affect circulation, biodistribution, cellular internalization, and trafficking. Small. 2013;9(9\u201310):1521\u201332.","journal-title":"Small"},{"issue":"1\u20132","key":"4450_CR127","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.ijpharm.2007.07.038","volume":"349","author":"F Esmaeili","year":"2008","unstructured":"Esmaeili F, et al. PLGA nanoparticles of different surface properties: preparation and evaluation of their body distribution. Int J Pharm. 2008;349(1\u20132):249\u201355.","journal-title":"Int J Pharm"},{"key":"4450_CR128","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.ejpb.2018.11.018","volume":"134","author":"R Hassan","year":"2019","unstructured":"Hassan R, et al. Prevention of hepatic stellate cell activation using JQ1- and atorvastatin-loaded chitosan nanoparticles as a promising approach in therapy of liver fibrosis. Eur J Pharm Biopharm. 2019;134:96\u2013106.","journal-title":"Eur J Pharm Biopharm"},{"issue":"1","key":"4450_CR129","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.jhepr.2019.02.004","volume":"1","author":"S Lefere","year":"2019","unstructured":"Lefere S, Tacke F. Macrophages in obesity and non-alcoholic fatty liver disease: crosstalk with metabolism. JHEP Rep. 2019;1(1):30\u201343.","journal-title":"JHEP Rep"},{"key":"4450_CR130","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.colsurfb.2017.07.014","volume":"158","author":"E Samuelsson","year":"2017","unstructured":"Samuelsson E, et al. Contribution of Kupffer cells to liposome accumulation in the liver. Colloids Surf B Biointerfaces. 2017;158:356\u201362.","journal-title":"Colloids Surf B Biointerfaces"},{"issue":"2","key":"4450_CR131","doi-asserted-by":"publisher","first-page":"e72","DOI":"10.1038\/mtna.2012.63","volume":"2","author":"JS Dolina","year":"2013","unstructured":"Dolina JS, et al. Lipidoid nanoparticles containing PD-L1 siRNA delivered in vivo enter Kupffer cells and enhance NK and CD8(+) T cell-mediated Hepatic antiviral immunity. Mol Ther Nucleic Acids. 2013;2(2):e72.","journal-title":"Mol Ther Nucleic Acids"},{"issue":"5","key":"4450_CR132","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1016\/j.nano.2016.01.013","volume":"12","author":"JK Park","year":"2016","unstructured":"Park JK, et al. Cellular distribution of injected PLGA-nanoparticles in the liver. Nanomedicine. 2016;12(5):1365\u201374.","journal-title":"Nanomedicine"},{"key":"4450_CR133","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.biomaterials.2015.04.025","volume":"59","author":"V Selvaraj","year":"2015","unstructured":"Selvaraj V, et al. Inhibition of MAP kinase\/NF-kB mediated signaling and attenuation of lipopolysaccharide induced severe sepsis by cerium oxide nanoparticles. Biomaterials. 2015;59:160\u201371.","journal-title":"Biomaterials"},{"issue":"1","key":"4450_CR134","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijpharm.2018.06.008","volume":"548","author":"TG de Carvalho","year":"2018","unstructured":"de Carvalho TG, et al. Spherical neutral gold nanoparticles improve anti-inflammatory response, oxidative stress and fibrosis in alcohol-methamphetamine-induced liver injury in rats. Int J Pharm. 2018;548(1):1\u201314.","journal-title":"Int J Pharm"},{"issue":"4","key":"4450_CR135","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.jcyt.2017.01.003","volume":"19","author":"J Sharkey","year":"2017","unstructured":"Sharkey J, et al. Functionalized superparamagnetic iron oxide nanoparticles provide highly efficient iron-labeling in macrophages for magnetic resonance-based detection in vivo. Cytotherapy. 2017;19(4):555\u201369.","journal-title":"Cytotherapy"},{"issue":"36","key":"4450_CR136","doi-asserted-by":"publisher","first-page":"5280","DOI":"10.3748\/wjg.v28.i36.5280","volume":"28","author":"JB Warner","year":"2022","unstructured":"Warner JB, et al. Liver-specific drug delivery platforms: applications for the treatment of alcohol-associated liver disease. World J Gastroenterol. 2022;28(36):5280\u201399.","journal-title":"World J Gastroenterol"},{"issue":"1-2","key":"4450_CR137","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.ijpharm.2010.11.025","volume":"404","author":"LF Lai","year":"2011","unstructured":"Lai LF, Guo HX. Preparation of new 5-fluorouracil-loaded zein nanoparticles for liver targeting. Int J Pharm. 2011;404(1\u20132):317\u201323.","journal-title":"Int J Pharm"},{"key":"4450_CR138","first-page":"903","volume":"10","author":"KR Jyothi","year":"2015","unstructured":"Jyothi KR, et al. Liver-targeted cyclosporine A-encapsulated poly (lactic-co-glycolic) acid nanoparticles inhibit hepatitis C virus replication. Int J Nanomed. 2015;10:903\u201321.","journal-title":"Int J Nanomed"},{"key":"4450_CR139","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.jviromet.2015.06.010","volume":"222","author":"X Hang","year":"2015","unstructured":"Hang X, et al. Antiviral activity of cuprous oxide nanoparticles against Hepatitis C Virus in vitro. J Virol Methods. 2015;222:150\u20137.","journal-title":"J Virol Methods"},{"issue":"Pt 6","key":"4450_CR140","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1099\/vir.0.79896-0","volume":"85","author":"X Jiao","year":"2004","unstructured":"Jiao X, et al. Enhanced hepatitis C virus NS3 specific Th1 immune responses induced by co-delivery of protein antigen and CpG with cationic liposomes. J Gen Virol. 2004;85(Pt 6):1545\u201353.","journal-title":"J Gen Virol"},{"issue":"9","key":"4450_CR141","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1038\/sj.mt.6300231","volume":"15","author":"MB Appaiahgari","year":"2007","unstructured":"Appaiahgari MB, Vrati S. DNAzyme-mediated inhibition of Japanese encephalitis virus replication in mouse brain. Mol Ther. 2007;15(9):1593\u20139.","journal-title":"Mol Ther"},{"key":"4450_CR142","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10040900","author":"W Xu","year":"2022","unstructured":"Xu W, et al. Liver-targeted nanoparticles facilitate the bioavailability and anti-HBV efficacy of baicalin in vitro and in vivo. Biomedicines. 2022. https:\/\/doi.org\/10.3390\/biomedicines10040900.","journal-title":"Biomedicines"},{"key":"4450_CR143","doi-asserted-by":"publisher","first-page":"856463","DOI":"10.3389\/fimmu.2022.856463","volume":"13","author":"L Gao","year":"2022","unstructured":"Gao L, et al. PreS\/2-21-guided siRNA nanoparticles target to inhibit hepatitis B virus infection and replication. Front Immunol. 2022;13:856463.","journal-title":"Front Immunol"},{"issue":"1","key":"4450_CR144","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s12951-021-00843-2","volume":"19","author":"T Sun","year":"2021","unstructured":"Sun T, et al. Nanomaterials and hepatic disease: toxicokinetics, disease types, intrinsic mechanisms, liver susceptibility, and influencing factors. J Nanobiotechnology. 2021;19(1):108.","journal-title":"J Nanobiotechnology"},{"issue":"3","key":"4450_CR145","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.3390\/nano5031351","volume":"5","author":"SW Shin","year":"2015","unstructured":"Shin SW, Song IH, Um SH. Role of physicochemical properties in nanoparticle toxicity. Nanomaterials (Basel). 2015;5(3):1351\u201365.","journal-title":"Nanomaterials (Basel)"},{"issue":"8","key":"4450_CR146","doi-asserted-by":"publisher","first-page":"3693","DOI":"10.7150\/thno.111685","volume":"15","author":"R Zhao","year":"2025","unstructured":"Zhao R, et al. Zwitterionic lipid nanoparticles for efficient siRNA delivery and hypercholesterolemia therapy with rational charge self-transformation. Theranostics. 2025;15(8):3693\u2013712.","journal-title":"Theranostics"},{"issue":"1\u20132","key":"4450_CR147","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.ijpharm.2014.05.011","volume":"471","author":"S Doktorovov\u00e1","year":"2014","unstructured":"Doktorovov\u00e1 S, et al. Cationic solid lipid nanoparticles interfere with the activity of antioxidant enzymes in hepatocellular carcinoma cells. Int J Pharm. 2014;471(1\u20132):18\u201327.","journal-title":"Int J Pharm"},{"issue":"6","key":"4450_CR148","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1021\/acs.bioconjchem.3c00174","volume":"34","author":"R Tenchov","year":"2023","unstructured":"Tenchov R, Sasso JM, Zhou QA. PEGylated lipid nanoparticle formulations: immunological safety and efficiency perspective. Bioconjug Chem. 2023;34(6):941\u201360.","journal-title":"Bioconjug Chem"},{"key":"4450_CR149","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1016\/0014-5793(90)81016-H","volume":"268","author":"ALEA Klibanov","year":"1990","unstructured":"Klibanov ALEA. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett. 1990;268:1990.","journal-title":"FEBS Lett"},{"key":"4450_CR150","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.jconrel.2021.11.042","volume":"341","author":"M Estap\u00e9 Senti","year":"2022","unstructured":"Estap\u00e9 Senti M, et al. Anti-PEG antibodies compromise the integrity of PEGylated lipid-based nanoparticles via complement. J Control Release. 2022;341:475\u201386.","journal-title":"J Control Release"},{"key":"4450_CR151","doi-asserted-by":"publisher","first-page":"1084799","DOI":"10.3389\/fphar.2022.1084799","volume":"13","author":"Z Huang","year":"2023","unstructured":"Huang Z, et al. Self-assembled FGF21 nanoparticles alleviate drug-induced acute liver injury. Front Pharmacol. 2023;13:1084799.","journal-title":"Front Pharmacol"},{"key":"4450_CR152","doi-asserted-by":"publisher","DOI":"10.2147\/ijn.s207644","author":"EI Hassanen","year":"2019","unstructured":"Hassanen EI, et al. Toxicopathological and immunological studies on different concentrations of chitosan-coated silver nanoparticles in rats. Int J Nanomed. 2019. https:\/\/doi.org\/10.2147\/ijn.s207644.","journal-title":"Int J Nanomed"},{"issue":"20","key":"4450_CR153","doi-asserted-by":"publisher","first-page":"12860","DOI":"10.1039\/D2RA00395C","volume":"12","author":"LG Powell","year":"2022","unstructured":"Powell LG, et al. An in vitro investigation of the hepatic toxicity of PEGylated polymeric redox responsive nanoparticles. RSC Adv. 2022;12(20):12860\u201370.","journal-title":"RSC Adv"},{"issue":"3","key":"4450_CR154","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.immuni.2016.02.004","volume":"44","author":"EC Carroll","year":"2016","unstructured":"Carroll EC, et al. The vaccine adjuvant chitosan promotes cellular immunity via DNA sensor cGAS-STING-dependent induction of type I interferons. Immunity. 2016;44(3):597\u2013608.","journal-title":"Immunity"},{"key":"4450_CR155","doi-asserted-by":"publisher","first-page":"5729","DOI":"10.2147\/IJN.S109001","volume":"11","author":"HD Han","year":"2016","unstructured":"Han HD, et al. Toll-like receptor 3-induced immune response by poly(d,l-lactide-co-glycolide) nanoparticles for dendritic cell-based cancer immunotherapy. Int J Nanomed. 2016;11:5729\u201342.","journal-title":"Int J Nanomed"},{"key":"4450_CR156","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S212907","author":"Y Yao","year":"2019","unstructured":"Yao Y, et al. The toxicity of metallic nanoparticles on liver: the subcellular damages, mechanisms, and outcomes. Int J Nanomed. 2019. https:\/\/doi.org\/10.2147\/IJN.S212907.","journal-title":"Int J Nanomed"},{"issue":"19","key":"4450_CR157","doi-asserted-by":"publisher","first-page":"8740","DOI":"10.1039\/D3NR00685A","volume":"15","author":"J Fernandez Alarcon","year":"2023","unstructured":"Fernandez Alarcon J, et al. Long-term retention of gold nanoparticles in the liver is not affected by their physicochemical characteristics. Nanoscale. 2023;15(19):8740\u201353.","journal-title":"Nanoscale"},{"issue":"10","key":"4450_CR158","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1002\/jat.3187","volume":"35","author":"KP Wen","year":"2015","unstructured":"Wen KP, et al. Accumulation and toxicity of intravenously-injected functionalized graphene oxide in mice. J Appl Toxicol. 2015;35(10):1211\u20138.","journal-title":"J Appl Toxicol"},{"issue":"10","key":"4450_CR159","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1007\/s11095-016-1958-5","volume":"33","author":"D Bobo","year":"2016","unstructured":"Bobo D, et al. Nanoparticle-based medicines: a review of FDA-approved materials and clinical trials to date. Pharm Res. 2016;33(10):2373\u201387.","journal-title":"Pharm Res"},{"key":"4450_CR160","doi-asserted-by":"publisher","first-page":"111168","DOI":"10.1016\/j.fct.2020.111168","volume":"137","author":"R Tassinari","year":"2020","unstructured":"Tassinari R, et al. Hazard identification of pyrogenic synthetic amorphous silica (NM-203) after sub-chronic oral exposure in rat: a multitarget approach. Food Chem Toxicol. 2020;137:111168.","journal-title":"Food Chem Toxicol"},{"issue":"7","key":"4450_CR161","doi-asserted-by":"publisher","first-page":"4023","DOI":"10.3390\/ijms23074023","volume":"23","author":"NK Yoo","year":"2022","unstructured":"Yoo NK, et al. Oral toxicokinetics, tissue distribution, and 28 day oral toxicity of two differently manufactured food additive silicon dioxides. Int J Mol Sci. 2022;23(7):4023.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"4450_CR162","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1093\/toxsci\/kfv258","volume":"150","author":"L Di Cristo","year":"2016","unstructured":"Di Cristo L, et al. Proinflammatory effects of pyrogenic and precipitated amorphous silica nanoparticles in innate immunity cells. Toxicol Sci. 2016;150(1):40\u201353.","journal-title":"Toxicol Sci"},{"issue":"10","key":"4450_CR163","doi-asserted-by":"publisher","first-page":"528","DOI":"10.3390\/biom9100528","volume":"9","author":"AM Mahmoud","year":"2019","unstructured":"Mahmoud AM, et al. Mesoporous silica nanoparticles trigger liver and kidney injury and fibrosis via altering TLR4\/NF-\u03baB, JAK2\/STAT3 and Nrf2\/HO-1 signaling in rats. Biomolecules. 2019;9(10):528.","journal-title":"Biomolecules"},{"key":"4450_CR164","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3390\/ijms25126699","volume":"25","author":"R Travassos","year":"2024","unstructured":"Travassos R, et al. Tailored viral-like particles as drivers of medical breakthroughs. Int J Mol Sci. 2024;25:12.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"4450_CR165","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1038\/s12276-024-01201-6","volume":"56","author":"HI Kim","year":"2024","unstructured":"Kim HI, et al. Recent advances in extracellular vesicles for therapeutic cargo delivery. Exp Mol Med. 2024;56(4):836\u201349.","journal-title":"Exp Mol Med"},{"issue":"8","key":"4450_CR166","doi-asserted-by":"publisher","first-page":"735","DOI":"10.21037\/atm-20-5422","volume":"9","author":"J Ding","year":"2021","unstructured":"Ding J, Wang J, Chen J. Exosomes as therapeutic vehicles in liver diseases. Ann Transl Med. 2021;9(8):735.","journal-title":"Ann Transl Med"},{"key":"4450_CR167","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15112623","author":"Z Wang","year":"2023","unstructured":"Wang Z, et al. Translational challenges and prospective solutions in the implementation of biomimetic delivery systems. Pharmaceutics. 2023. https:\/\/doi.org\/10.3390\/pharmaceutics15112623.","journal-title":"Pharmaceutics"},{"key":"4450_CR168","doi-asserted-by":"publisher","first-page":"790","DOI":"10.3389\/fphar.2018.00790","volume":"9","author":"S Hua","year":"2018","unstructured":"Hua S, et al. Current trends and challenges in the clinical translation of nanoparticulate nanomedicines: pathways for translational development and commercialization. Front Pharmacol. 2018;9:790.","journal-title":"Front Pharmacol"},{"issue":"1","key":"4450_CR169","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.apsb.2018.11.001","volume":"9","author":"J Tao","year":"2019","unstructured":"Tao J, Chow SF, Zheng Y. Application of flash nanoprecipitation to fabricate poorly water-soluble drug nanoparticles. Acta Pharm Sin B. 2019;9(1):4\u201318.","journal-title":"Acta Pharm Sin B"},{"issue":"5","key":"4450_CR170","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1080\/17425247.2018.1446936","volume":"15","author":"JP Martins","year":"2018","unstructured":"Martins JP, Torrieri G, Santos HA. The importance of microfluidics for the preparation of nanoparticles as advanced drug delivery systems. Expert Opin Drug Deliv. 2018;15(5):469\u201379.","journal-title":"Expert Opin Drug Deliv"},{"issue":"4","key":"4450_CR171","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11051-025-06293-3","volume":"27","author":"C de Souza Cardoso Delfino","year":"2025","unstructured":"de Souza Cardoso Delfino C, et al. Scaling nanopharmaceutical production for personalized medicine: challenges and strategies. J Nanoparticle Res. 2025;27(4):1\u201319.","journal-title":"J Nanoparticle Res"},{"issue":"6","key":"4450_CR172","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1021\/acsmaterialsau.3c00032","volume":"3","author":"M Mehta","year":"2023","unstructured":"Mehta M, et al. Lipid-based nanoparticles for drug\/gene delivery: an overview of the production techniques and difficulties encountered in their industrial development. ACS Mater Au. 2023;3(6):600\u201319.","journal-title":"ACS Mater Au"},{"issue":"9","key":"4450_CR173","doi-asserted-by":"publisher","first-page":"5505","DOI":"10.1021\/acs.chemrev.3c00705","volume":"124","author":"MA Beach","year":"2024","unstructured":"Beach MA, et al. Polymeric nanoparticles for drug delivery. Chem Rev. 2024;124(9):5505\u2013616.","journal-title":"Chem Rev"},{"key":"4450_CR174","doi-asserted-by":"publisher","first-page":"100048","DOI":"10.1016\/j.onano.2022.100048","volume":"7","author":"Y Herdiana","year":"2022","unstructured":"Herdiana Y, et al. Scale-up polymeric-based nanoparticles drug delivery systems: development and challenges. OpenNano. 2022;7:100048.","journal-title":"OpenNano"},{"key":"4450_CR175","first-page":"11","volume":"1","author":"CA Charitidis","year":"2014","unstructured":"Charitidis CA, et al. Manufacturing nanomaterials: from research to industry. Manuf Rev. 2014;1:11.","journal-title":"Manuf Rev"},{"key":"4450_CR176","doi-asserted-by":"publisher","first-page":"130835","DOI":"10.1016\/j.biortech.2024.130835","volume":"403","author":"H Kachroo","year":"2024","unstructured":"Kachroo H, et al. Organic\/metallic component analysis of lignocellulosic biomass: a thermochemical-perspective-based study on rice and bamboo waste. Bioresour Technol. 2024;403:130835.","journal-title":"Bioresour Technol"},{"issue":"32","key":"4450_CR177","doi-asserted-by":"publisher","first-page":"20861","DOI":"10.1021\/acsnano.4c02380","volume":"18","author":"J Liu","year":"2024","unstructured":"Liu J, et al. Delivery strategy to enhance the therapeutic efficacy of liver fibrosis via nanoparticle drug delivery systems. ACS Nano. 2024;18(32):20861\u201385.","journal-title":"ACS Nano"},{"key":"4450_CR178","doi-asserted-by":"publisher","first-page":"e70054","DOI":"10.1002\/agt2.70054","volume":"20","author":"MB Zewail","year":"2025","unstructured":"Zewail MB, et al. Cell membrane-coated lipid nanoparticles for drug delivery. Aggregate. 2025;20:e70054.","journal-title":"Aggregate"},{"key":"4450_CR179","doi-asserted-by":"publisher","first-page":"1123805","DOI":"10.3389\/fimmu.2023.1123805","volume":"14","author":"R Gupta","year":"2023","unstructured":"Gupta R, et al. Platforms, advances, and technical challenges in virus-like particles-based vaccines. Front Immunol. 2023;14:1123805.","journal-title":"Front Immunol"},{"issue":"8","key":"4450_CR180","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1021\/ac0207980","volume":"75","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, et al. Spectroscopic approach for on-line monitoring of particle size during the processing of pharmaceutical nanoparticles. Anal Chem. 2003;75(8):1777\u201385.","journal-title":"Anal Chem"},{"key":"4450_CR181","doi-asserted-by":"publisher","first-page":"122818","DOI":"10.1016\/j.ijpharm.2023.122818","volume":"636","author":"A Dedeloudi","year":"2023","unstructured":"Dedeloudi A, Weaver E, Lamprou DA. Machine learning in additive manufacturing & microfluidics for smarter and safer drug delivery systems. Int J Pharm. 2023;636:122818.","journal-title":"Int J Pharm"},{"key":"4450_CR182","doi-asserted-by":"publisher","first-page":"757469","DOI":"10.3389\/fphys.2021.757469","volume":"12","author":"S Bhandari","year":"2021","unstructured":"Bhandari S, et al. The scavenger function of liver sinusoidal endothelial cells in health and disease. Front Physiol. 2021;12:757469.","journal-title":"Front Physiol"},{"key":"4450_CR183","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1743-8977-4-10","volume":"4","author":"E Sadauskas","year":"2007","unstructured":"Sadauskas E, et al. Kupffer cells are central in the removal of nanoparticles from the organism. Part Fibre Toxicol. 2007;4:1\u20137.","journal-title":"Part Fibre Toxicol"},{"key":"4450_CR184","doi-asserted-by":"publisher","first-page":"173832","DOI":"10.1016\/j.ejphar.2020.173832","volume":"893","author":"D Ezhilarasan","year":"2021","unstructured":"Ezhilarasan D. Advantages and challenges in nanomedicines for chronic liver diseases: a hepatologist\u2019s perspectives. Eur J Pharmacol. 2021;893:173832.","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"4450_CR185","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/cmi.2016.5","volume":"13","author":"PA Knolle","year":"2016","unstructured":"Knolle PA, Wohlleber D. Immunological functions of liver sinusoidal endothelial cells. Cell Mol Immunol. 2016;13(3):347\u201353.","journal-title":"Cell Mol Immunol"},{"key":"4450_CR186","doi-asserted-by":"publisher","first-page":"116702","DOI":"10.1016\/j.biopha.2024.116702","volume":"175","author":"X Meng","year":"2024","unstructured":"Meng X, et al. Targeted delivery strategies: the interactions and applications of nanoparticles in liver diseases. Biomed Pharmacother. 2024;175:116702.","journal-title":"Biomed Pharmacother"},{"key":"4450_CR187","doi-asserted-by":"publisher","first-page":"603039","DOI":"10.3389\/fimmu.2020.603039","volume":"11","author":"NM La-Beck","year":"2021","unstructured":"La-Beck NM, Islam MR, Markiewski MM. Nanoparticle-induced complement activation: implications for cancer nanomedicine. Front Immunol. 2021;11:603039.","journal-title":"Front Immunol"},{"issue":"4","key":"4450_CR188","doi-asserted-by":"publisher","first-page":"e327","DOI":"10.1002\/mco2.327","volume":"4","author":"L Xuan","year":"2023","unstructured":"Xuan L, et al. Nanoparticles-induced potential toxicity on human health: applications, toxicity mechanisms, and evaluation models. MedComm. 2023;4(4):e327.","journal-title":"MedComm"},{"issue":"12","key":"4450_CR189","doi-asserted-by":"publisher","first-page":"5552","DOI":"10.1039\/c3cs60064e","volume":"42","author":"M Elsabahy","year":"2013","unstructured":"Elsabahy M, Wooley KL. Cytokines as biomarkers of nanoparticle immunotoxicity. Chem Soc Rev. 2013;42(12):5552\u201376.","journal-title":"Chem Soc Rev"},{"key":"4450_CR190","doi-asserted-by":"publisher","first-page":"176898","DOI":"10.1016\/j.scitotenv.2024.176898","volume":"954","author":"J Luan","year":"2024","unstructured":"Luan J, et al. Systemic toxicity of biodegradable polyglycolic acid microplastics on the gut-liver-brain axis in zebrafish. Sci Total Environ. 2024;954:176898.","journal-title":"Sci Total Environ"},{"key":"4450_CR191","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1016\/j.biopha.2018.07.081","volume":"106","author":"Y Xia","year":"2018","unstructured":"Xia Y, et al. Yu Gan Long reduces rat liver fibrosis by blocking TGF-\u03b21\/Smad pathway and modulating the immunity. Biomed Pharmacother. 2018;106:1332\u20138.","journal-title":"Biomed Pharmacother"},{"issue":"53","key":"4450_CR192","doi-asserted-by":"publisher","first-page":"80448","DOI":"10.1007\/s11356-022-21388-3","volume":"29","author":"DH Assar","year":"2022","unstructured":"Assar DH, et al. Silver nanoparticles induced hepatoxicity via the apoptotic\/antiapoptotic pathway with activation of TGF\u03b2-1 and \u03b1-SMA triggered liver fibrosis in Sprague Dawley rats. Environ Sci Pollut Res. 2022;29(53):80448\u201365.","journal-title":"Environ Sci Pollut Res"},{"key":"4450_CR193","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S443168","author":"K Jakic","year":"2024","unstructured":"Jakic K, et al. Long-term accumulation, biological effects and toxicity of bsa-coated gold nanoparticles in the mouse liver, spleen, and kidneys. Int J Nanomed. 2024. https:\/\/doi.org\/10.2147\/IJN.S443168.","journal-title":"Int J Nanomed"},{"issue":"12","key":"4450_CR194","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.3390\/v15122315","volume":"15","author":"A-Q Zhuang","year":"2023","unstructured":"Zhuang A-Q, et al. Current status and challenges in anti-hepatitis B virus agents based on inactivation\/inhibition or elimination of hepatitis B virus covalently closed circular DNA. Viruses. 2023;15(12):2315.","journal-title":"Viruses"},{"issue":"9","key":"4450_CR195","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1038\/mt.2012.173","volume":"20","author":"D Grimm","year":"2012","unstructured":"Grimm D. All for one, one for all: new combinatorial RNAi therapies combat hepatitis C virus evolution. Mol Ther. 2012;20(9):1661\u20133.","journal-title":"Mol Ther"},{"issue":"7","key":"4450_CR196","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1136\/gut.2004.060327","volume":"54","author":"A Erhardt","year":"2005","unstructured":"Erhardt A, et al. Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D. Gut. 2005;54(7):1009\u201313.","journal-title":"Gut"},{"issue":"5","key":"4450_CR197","doi-asserted-by":"publisher","first-page":"a021436","DOI":"10.1101\/cshperspect.a021436","volume":"5","author":"CL Lin","year":"2015","unstructured":"Lin CL, et al. Hepatitis B virus genotypes and variants. Cold Spring Harb Perspect Med. 2015;5(5):a021436.","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"4","key":"4450_CR198","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.4251\/wjgo.v16.i4.1097","volume":"16","author":"CHC Sukowati","year":"2024","unstructured":"Sukowati CHC, et al. Hepatitis B virus genotypes in precision medicine of hepatitis B-related hepatocellular carcinoma: where we are now. World J Gastrointest Oncol. 2024;16(4):1097\u2013103.","journal-title":"World J Gastrointest Oncol"},{"issue":"6","key":"4450_CR199","doi-asserted-by":"publisher","first-page":"e1254","DOI":"10.1093\/infdis\/jiae253","volume":"230","author":"JL Mbisa","year":"2024","unstructured":"Mbisa JL, et al. Identification of 2 novel subtypes of hepatitis C virus genotype 8 and a potential new genotype successfully treated with direct acting antivirals. J Infect Dis. 2024;230(6):e1254\u201362.","journal-title":"J Infect Dis"},{"key":"4450_CR200","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.antiviral.2014.05.015","volume":"108","author":"E Poveda","year":"2014","unstructured":"Poveda E, et al. Update on hepatitis C virus resistance to direct-acting antiviral agents. Antiviral Res. 2014;108:181\u201391.","journal-title":"Antiviral Res"},{"key":"4450_CR201","doi-asserted-by":"crossref","unstructured":"Lin, W., E.M. Weinberg, and R.T. Chung 2013 Pathogenesis of accelerated fibrosis in HIV\/HCV co-infection. J Infect Dis 207 Suppl 1(Suppl 1) S13\u20138","DOI":"10.1093\/infdis\/jis926"},{"key":"4450_CR202","doi-asserted-by":"crossref","unstructured":"Tural, C.e.a., Differences in virological response to pegylated interferon and ribavirin between hepatitis C virus (HCV)-monoinfected and HCV-HIV-coinfected patients. Antiviral therapy, 2008. 13,8: p. 1047\u201355.","DOI":"10.1177\/135965350801300818"},{"key":"4450_CR203","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/liv.15345","volume":"43","author":"V Soriano","year":"2023","unstructured":"Soriano V, et al. Treatment of hepatitis delta and HIV infection. Liver Int. 2023;43:108\u201315.","journal-title":"Liver Int"},{"key":"4450_CR204","doi-asserted-by":"publisher","first-page":"114083","DOI":"10.1016\/j.addr.2021.114083","volume":"181","author":"MA Younis","year":"2022","unstructured":"Younis MA, et al. Clinical translation of nanomedicines: challenges, opportunities, and keys. Adv Drug Deliv Rev. 2022;181:114083.","journal-title":"Adv Drug Deliv Rev"},{"issue":"1","key":"4450_CR205","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/hep.31008","volume":"72","author":"MF Yuen","year":"2020","unstructured":"Yuen MF, et al. RNA interference therapy with ARC-520 results in prolonged hepatitis B surface antigen response in patients with chronic hepatitis B infection. Hepatology. 2020;72(1):19\u201331.","journal-title":"Hepatology"},{"key":"4450_CR206","unstructured":"A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Positive, Chronic Hepatitis B Virus Infection. 2019. [cited 2025 30\/06\/2025]; Available from: https:\/\/clinicaltrials.gov\/study\/NCT02604212."},{"key":"4450_CR207","unstructured":"Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic Chronic Hepatitis B Virus (HBV) (MONARCH). 2019. [cited 2025 30\/06\/2025]; Available from: https:\/\/clinicaltrials.gov\/study\/NCT02577029."},{"key":"4450_CR208","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12985-017-0753-1","volume":"14","author":"MH Elberry","year":"2017","unstructured":"Elberry MH, Darwish NH, Mousa SA. Hepatitis C virus management: potential impact of nanotechnology. Virol J. 2017;14:1\u201310.","journal-title":"Virol J"},{"issue":"10","key":"4450_CR209","doi-asserted-by":"publisher","first-page":"3640","DOI":"10.1021\/acsinfecdis.4c00514","volume":"10","author":"EP Thi","year":"2024","unstructured":"Thi EP, et al. Control of hepatitis B virus with imdusiran, a small interfering RNA therapeutic. ACS Infect Dis. 2024;10(10):3640\u20139.","journal-title":"ACS Infect Dis"},{"key":"4450_CR210","doi-asserted-by":"publisher","first-page":"1633001","DOI":"10.3389\/fphar.2025.1633001","volume":"16","author":"L Zhang","year":"2025","unstructured":"Zhang L, et al. Small nucleic acid drugs\u2014the dawn of functional cure of chronic hepatitis B. Front Pharmacol. 2025;16:1633001.","journal-title":"Front Pharmacol"},{"issue":"409","key":"4450_CR211","doi-asserted-by":"publisher","first-page":"eaan0241","DOI":"10.1126\/scitranslmed.aan0241","volume":"9","author":"CI Wooddell","year":"2017","unstructured":"Wooddell CI, et al. RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg. Sci Transl Med. 2017;9(409):eaan0241.","journal-title":"Sci Transl Med"},{"key":"4450_CR212","doi-asserted-by":"publisher","first-page":"107534","DOI":"10.1016\/j.biotechadv.2020.107534","volume":"40","author":"Y Weng","year":"2020","unstructured":"Weng Y, et al. The challenge and prospect of the mRNA therapeutics landscape. Biotechnol Adv. 2020;40:107534.","journal-title":"Biotechnol Adv"},{"key":"4450_CR213","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1007\/s13346-020-00818-0","volume":"11","author":"M Chakravarty","year":"2021","unstructured":"Chakravarty M, Vora A. Nanotechnology-based antiviral therapeutics. Drug Deliv Transl Res. 2021;11:748\u201387.","journal-title":"Drug Deliv Transl Res"},{"issue":"4","key":"4450_CR214","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/s41565-021-00899-z","volume":"16","author":"F Salamanca-Buentello","year":"2021","unstructured":"Salamanca-Buentello F, Daar AS. Nanotechnology, equity and global health. Nat Nanotechnol. 2021;16(4):358\u201361.","journal-title":"Nat Nanotechnol"},{"issue":"1","key":"4450_CR215","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.biotechadv.2014.11.003","volume":"33","author":"UH Yildiz","year":"2015","unstructured":"Yildiz UH, et al. Recent advances in micro\/nanotechnologies for global control of hepatitis B infection. Biotechnol Adv. 2015;33(1):178\u201390.","journal-title":"Biotechnol Adv"},{"issue":"22","key":"4450_CR216","doi-asserted-by":"publisher","first-page":"11121","DOI":"10.3390\/ijms262211121","volume":"26","author":"Y Han","year":"2025","unstructured":"Han Y, Kim DH, Pack SP. Nanomaterials in drug delivery: leveraging artificial intelligence and big data for predictive design. Int J Mol Sci. 2025;26(22):11121. https:\/\/doi.org\/10.3390\/ijms262211121.","journal-title":"Int J Mol Sci"},{"key":"4450_CR217","doi-asserted-by":"publisher","first-page":"24010003","DOI":"10.69598\/sehs.18.24010003","volume":"18","author":"DU Kapoor","year":"2024","unstructured":"Kapoor DU, Sharma JB, Gandhi SM, Prajapati BG, Thanawuth K, Limmatvapirat S, et al. AI-driven design and optimization of nanoparticle-based drug delivery systems. Sci Eng Health Stud. 2024;18:24010003.","journal-title":"Sci Eng Health Stud"},{"issue":"4","key":"4450_CR218","first-page":"336","volume":"22","author":"G Di Pasquale","year":"2021","unstructured":"Di Pasquale G, et al. Timing of coronary angiography in the 2020 ESC guidelines on non-ST-elevation acute coronary syndromes: when guidelines are not helpful. G Ital Cardiol (Rome). 2021;22(4):336.","journal-title":"G Ital Cardiol (Rome)"},{"key":"4450_CR219","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.sleep.2022.05.017","volume":"98","author":"S Morris","year":"2022","unstructured":"Morris S, et al. Validation of the pediatric narcolepsy screening questionnaire (PNSQ): a cross-sectional, observational study. Sleep Med. 2022;98:127\u201338.","journal-title":"Sleep Med"},{"issue":"1","key":"4450_CR220","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1186\/s12889-022-14460-7","volume":"22","author":"\u00c5 Hermansen","year":"2022","unstructured":"Hermansen \u00c5, et al. Constructing and validating an occupational mechanical job exposure index based on five Norwegian nationwide surveys of living conditions on work environment. BMC Public Health. 2022;22(1):2028.","journal-title":"BMC Public Health"}],"container-title":["Discover Nano"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s11671-026-04450-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s11671-026-04450-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s11671-026-04450-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T07:03:16Z","timestamp":1770361396000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s11671-026-04450-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,6]]},"references-count":220,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4450"],"URL":"https:\/\/doi.org\/10.1186\/s11671-026-04450-8","relation":{},"ISSN":["2731-9229"],"issn-type":[{"value":"2731-9229","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,6]]},"assertion":[{"value":"24 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors consent to participate in this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"All authors consent to the publication of this work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no relevant financial or non-financial interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"31"}}